FORT LAUDERDALE, Fla. — On this Healio Video Perspective from the Retina World Congress, Dilraj S. Grewal, MD, FASRS, supplies an replace on the progress of therapies for noninfectious uveitis.
Whereas some therapies failed trials, others demonstrated promising outcomes, together with dazdotuftide (Tarsier Pharma), which lowered irritation in sufferers with uveitis with out elevating IOP in a part 3 trial.
“We’ve got a number of thrilling therapies which are at the moment in investigation throughout the spectrum of oral, injectable intravitreals in addition to topicals for our uveitis sufferers,” Grewal mentioned.
Sources/Disclosures
Collapse
Grewal DS. New therapeutics for non-infectious uveitis in 2025. Introduced at: Retina World Congress; Might 8-11, 2025; Fort Lauderdale, Florida.
Disclosures:
Grewal stories consulting for Genentech/Roche.
